Index

Note: Page numbers of article titles are in boldface type.

A
Abuse, autism spectrum as victims of, 1178
Acamptosate, for alcohol withdrawal, 1106–1109
Acetylcholine inhibitors, 996
Addison disease, neuropsychiatric manifestations of, 1200–1201
Adjustment disorders, 988, 1071–1074
Adrenal insufficiency, neuropsychiatric manifestations of, 1200–1201
Adult ADHD Rating Scales, 968
Adult Self Report, for ADHD screening, 968
Advanced sleep phase syndrome, 1131
Affective dysregulation, in borderline personality disorder, 1052
Alcohol use. See Substance abuse.
Alzheimer disease, 1152–1153
Amodafinil, 1136
ANK3 gene, in bipolar disorder, 1026
Antianxiety medications, 929
Anticipatory grief, 1069–1071
Anticonvulsants, 940–942, 1105
Antidepressants, 928–931
efficacy of, 995
failure of, 997–998
for bipolar disorder, 1032–1034
for borderline personality disorder, 1055–1056
for depression, 994–998, 1159–1161
for grief, 1071
for insomnia, 1127, 1131
for multiple somatic symptoms, 1089
for seasonal affective disorder, 1068–1069
for sleep disorders, 1128
mechanism of action of, 995
medication interactions with, 997
side effects of, 931, 995–997
Antipsychotics, 930, 943–951
atypical, 943–944, 948–949, 1035–1036, 1128
drug interactions with, 946
for autism spectrum, 1185–1186
for bipolar disorder, 1032, 1035–1036
for borderline personality disorder, 1056
for dementia, 950–951
for sleep disorders, 1128
side effects of, 945
Anxiety disorders, 1007–1023
  autism spectrum with, 1177
  comorbid disorders with, 1008
  costs of, 1010
  course of, 1011–1012
  diagnosis of, 1008–1009
  Diagnostic and Statistical Manual of Psychiatric Disorders changes in, 1010–1011
  epidemiology of, 1011
  prevalence of, 1007
  prognosis for, 1011–1012
  screening for, 964–967, 974–976, 1010
  sleep disorders in, 1125, 1133–1135
  somatic symptoms with, 1080, 1085–1089
  subthreshold symptoms of, 1010
  suicide risk in, 1010
  versus bipolar disorder, 1033
Anxiolytics, for anxiety disorders, 1013, 1015–1016
Anxious distress, in major depression, 982–983
Aripiprazole, 944, 950
  for autism spectrum, 1185
  for bipolar disorder, 1034–1035
  for sleep disorders, 1128
Asberger’s disorder. See Autism spectrum.
Asenapine, for bipolar disorder, 1034–1035
Assistive and augmentative communication technology, for autism spectrum, 1171, 1174
Attention-deficit/hyperactivity disorder
  screening for, 967–968
  sleep disorders in, 1125, 1133–1135
  versus bipolar disorder, 1033
AUDIT-C scale, 1099–1101
Autism Diagnostic Observation Schedule, 1171
Autism spectrum, 1169–1191
  assistive technologies for, 1171, 1174
  behavioral challenges in, 1184–1186
  conditions associated with, 1174–1175, 1177–1178
  diagnosis of, 1170–1173
  ethical issues in, 1186–1187
  health care facilitation in, 1178–1184
  legal issues in, 1186–1187
  resources for, 1176
Autogenic training, for depression, 992
Autonomy, for autistic persons, 1186–1187

B
BATEH technique, for multiple somatic symptoms, 1087
Beck Anxiety Inventory, 965–966
Beck Depression Rating Scale, 992
Behavioral challenges, in autism spectrum, 1184–1186
Behavioral interventions, for depression, 990–992
Index

Benzodiazepines, 937–938
  for alcohol withdrawal, 1104
  for anxiety disorders, 1014, 1017
  for borderline personality disorder, 1055
Bereavement, 989, 1069–1071
Bipolar disorder, 1025–1048
  borderline personality disorder with, 1052–1053, 1056–1057
  comorbidities with, 1031
  diagnosis of, 1027–1028
  differential diagnosis of, 1031, 1033
  epidemiology of, 1026
  genetics of, 1026
  impact of, 1026–1027
  in pregnancy, 1038–1039
  maintenance strategies for, 1038
  medical workup for, 1029, 1031
  mood stabilizers for, 938–943
  nomenclature of, 1028
  phenotypes of, 1031
  risk assessment in, 1030
  screening for, 1028–1030
  sleep disorders in, 1130–1133
  systems of care for, 1041
  treatment of, 1032–1042
Bipolar Spectrum Diagnostic Scale, 1029
Borderline personality disorder, 1049–1064
  behavioral problems with, 1058–1059
  bipolar disorder with, 1056–1057
  case study of, 1040–1050
  categories of, 1051–1052
  clinical characteristics in, 1051–1052
  comorbid conditions with, 1052–1053
  diagnostic criteria in, 1051–1052
  epidemiology of, 1050
  pathophysiology of, 1053–1054
  remission in, 1050–1051
  suicide risk in, 1051
  treatment of, 1054–1060
  versus bipolar disorder, 1033
Brain, abnormalities of, in borderline personality disorder, 1053
Brief Grief Questionnaire, 1070
Buprenorphine, for opioid use disorders, 1115, 1117
Bupropion
  for depression, 996, 998
  for insomnia, 1126
  for seasonal affective disorder, 1068
  for sleep disorders, 1128
  indications for, 933
  mechanism of action of, 935–936
  side effects of, 932, 996, 998
CACNA1C gene, in bipolar disorder, 1026
CAGE questionnaire, 1161
Calcium disorders, neuropsychiatric manifestations of, 1202
Canadian Task Force on Preventive Health Care, screening recommendations of, 974–975
Cancer
  adjustment disorder in, 1073
  paraneoplastic syndromes in, 1203
Carbamazepine, 938–942, 1032, 1034, 1036, 1039
Childhood disintegrative disorder. See Autism spectrum.
Chlordiazepoxide, for alcohol withdrawal, 1105
Chlorpromazine, 948
Circadian rhythm disorders, 1125
  in attention-deficit/hyperactivity disorder, 1136
  in depression, 1131–1132
Citalopram, 932–933
Client-centered therapy, for depression, 992–993
Clinical Institute Withdrawal Assessment for Alcohol, Revised, 1103–1104
Clonidine, 1115
Clozapine, 949
Cobalamin deficiency, neuropsychiatric manifestations of, 1201
Cognition, disturbed, in borderline personality disorder, 1052
Cognitive behavioral therapy
  for anxiety disorders, 1013–1014, 1017
  for autism spectrum, 1186
  for bipolar disorder, 1040
  for depression, 992–993
  for insomnia, 1124, 1126–1128
  for multiple somatic symptoms, 1089
  for seasonal affective disorder, 1068–1069
Collaborative care
  for bipolar disorder, 1041
  for depression, 1161
  for multiple somatic symptoms, 1090–1091
Collaborative Opioid Prescribing Education program, 1111–1112
Communication, in autism spectrum, 1178–1183
Complementary and alternative medicine
  for anxiety disorders, 1015
  for seasonal affective disorder, 1068
Complex grief, 1069–1071
Consultation, for bipolar disorder, 1041
Coordinated Anxiety Learning and Management study, 1015
CRAFFT screening tool, 1101
Cryptococcal infections, neuropsychiatric manifestations of, 1195–1196
Current Symptoms Scale, for ADHD screening, 968
Cushing syndrome, neuropsychiatric manifestations of, 1200
Cyclothymic disorders, 1028
Cymbalta, indications for, 933
D
Decision making, for autistic persons, 1186–1187
Delayed sleep phase syndrome, 1131
Delirium, 988, 1146–1148
Delusions, in borderline personality disorder, 1052
Dementia, 1148–1156
  antipsychotics for, 950–951
  epidemiology of, 1148–1149
  evaluation for, 1149–1150
  psychiatric disorders with, 1156
  types of, 1150–1156
  versus delirium, 1146–1148
Demoralization, depression and, 988
Dental care, for autistic persons, 1182
Depression. See also Major depression.
  antidepressants for. See Antidepressants.
  antipsychotics for, 949–950
  atypical, 982–983
  comorbidity with, 1158
  in bipolar disorder, 1027–1028, 1032–1042
  in older adults, 1156–1161
  in seasonal affective disorder, 1066–1069
  minor, 989
  persistent, 989
  screening for, 961–964, 973–975, 1157
  sleep disorders in, 1125–1127, 1130–1133
  somatic symptoms with, 1080, 1084–1089
  subsyndromal, 989
  subtypes of, 982–983
  suicide risk in, 1158–1159
  treatment of, 1159–1161
  treatment-resistant, 997–998
  versus grief, 1070–1071
Desipramine, 996
Desvenlafaxine, indications for, 933
Dialectic behavior therapy, for borderline personality disorder, 1054–1055
Diet, for depression, 991
Disulfiram, for alcohol withdrawal, 1106–1109
Donepezil, for dementia, 1155
Dopamine agonists, for restless leg syndrome, 1132
Dopamine inhibitors, side effects of, 996
Dragon Naturally Speaking device, 1171
Drugs
  abuse of. See Substance abuse disorders.
  for psychiatric disorders. See Psychopharmacology; specific drugs and disorders.
Duloxetine, 932, 996
Dysthymia, 989, 1028
Dysthymic disorder, 989
Electroconvulsive therapy, for bipolar disorder, 1038–1039
EMBOLDEN study, 1041–1042
Empathy, for multiple somatic symptoms, 1087
Encephalitis, limbic, 1203
Environmental factors, in borderline personality disorder, 1054
Epilepsy, in autism spectrum, 1175, 1177
Escitalopram
   for insomnia, 1134
   indications for, 933
   side effects of, 932
Eszopiclone, for insomnia, 1127, 1129, 1134
Ethical issues, in autism spectrum, 1186–1187
Exercise
   for anxiety disorders, 1015
   for depression, 991
   for insomnia, 1126
Exposure and response therapy, for anxiety disorders, 1018

Falls, from antidepressants, 997
Family-focused therapy, for bipolar disorder, 1040
Feeding problems, in autism spectrum, 1177
Fluoxetine
   for bipolar disorder, 1034
   for depression, 996
   for seasonal affective disorder, 1068
   indications for, 933
   side effects of, 932, 996
Fluphenazine, 948
Fluvoxamine, 932–933
Frontotemporal dementia, 1152, 1156

G
Gabapentin
   for alcohol withdrawal, 1105, 1109
   for anxiety disorders, 1014
Galantamine, for dementia, 1155
Gastrointestinal disorders, in autism spectrum, 1177
Generalized anxiety disorder
   cost of, 1010
   course of, 1011
   diagnosis of, 1008–1009
   epidemiology of, 1011
   screening for, 1010–1011
   somatic symptoms with, 1086
   treatment of, 1013, 1015–1016
Generalized Anxiety Disorder screening tool, 965–967, 969, 974
Genetics
of bipolar disorder, 1026
  of borderline personality disorder, 1053
Geriatric Anxiety Inventory, 972
Geriatric Depression Scale, 971–972
Geriatrics. See Older adults.
Grief reaction, 989, 1069–1071
Guardians, for autistic persons, 1186–1187

H
Hallucinations, in borderline personality disorder, 1052
Haloperidol, 944, 1034, 1036
Hamilton Depression Rating Scale, 992
HIV-associated neurocognitive disorder, 1195
Hospital Anxiety and Depression Scale, 966, 1010
Human immunodeficiency virus infections, neuropsychiatric manifestations of, 1194–1196
Hydroxyzine, for anxiety disorders, 1014
Hypercalcemia, neuropsychiatric manifestations of, 1202
Hypercortisolism, neuropsychiatric manifestations of, 1200
Hypersensitivity, interpersonal, in borderline personality disorder, 1051–1052
Hypersomnialna, in depression, 988, 991
Hyperthyroidism, neuropsychiatric manifestations of, 1199–1200
Hypocalcemia, neuropsychiatric manifestations of, 1202
Hypocortisolism, neuropsychiatric manifestations of, 1200–1201
Hypomaniac episode, in bipolar disorder, 1027–1028, 1032–1042
Hyponatremia, from antidepressants, 997
Hypothyroidism, neuropsychiatric manifestations of, 1199–1200

I
Illness anxiety disorder, 1082
Impulsivity, 1136
  in borderline personality disorder, 1052
  sleep disorders in, 1125
Infections, neuropsychiatric manifestations of, 1194–1197
Insomnia, 1124–1127
  in anxiety disorders, 1133–1134
  in attention-deficit/hyperactivity disorder, 1135–1136
  in depression, 988, 991, 1130–1131
  in schizophrenia, 1135
Interpersonal hypersensitivity, in borderline personality disorder, 1051–1052
Interpersonal therapy
  for bipolar disorder, 1040
  for depression, 992–993
Isolated sleep paralysis
  in anxiety, 1134–1135
  in depression, 1133

K
Korsakoff syndrome, 1201
Kubler-Ross stages of grief, 1069–1070
L
Lamotrigine, 938–942
   for bipolar disorder, 1034, 1036, 1038–1039
   for borderline personality disorder, 1055
Legal issues, in autism spectrum, 1186–1187
Lewy bodies, dementia with, 1152–1153, 1155
Lifestyle changes, for depression, 990–992
Light therapy, for seasonal affective disorder, 1067–1069, 1132
Limbic encephalitis, 1203
Lithium, 938–941, 1032, 1034, 1037–1039
Lorazepam, for alcohol withdrawal, 1105
Lurasidone, for bipolar disorder, 1034–1035
Lyme disease, neuropsychiatric manifestations of, 1197

M
Major depression, 981–1005
   clinical presentation of, 982
   comorbidity with, 987–989
   course of, 984
   diagnostic criteria of, 982
   differential diagnosis of, 987–989
   epidemiology of, 984
   impairment in, 983–984
   pathophysiology of, 987
   recurrent, 984
   risk factors for, 985
   screening for, 984–987
   suicide risk in, 990
   symptoms of, 984
   syndrome of, 982
   treatment of, 990–998
   versus bipolar disorder, 1033
   with anxious distress, 982–983
Manic episode, in bipolar disorder, 1027–1028, 1032–1042
Manic switch, 1027, 1041–1042
Maprotiline, indications for, 933
Medical conditions, with neuropsychiatric manifestations, 1193–1208
   endocrinologic, 1194.1199–1201
   infectious, 1194–1197
   metabolic, 1194, 1201–1202
   neoplastic, 1194, 1203
   rheumatologic, 1194, 1197–1199
Medication switch, antidepressants in, 998
Memantine, for dementia, 1155
Mentalization-based therapy, for borderline personality disorder, 1054–1055
Methadone, for opioid use disorders, 1114–1116
Mild cognitive impairment, 1150–1153
Mindfulness interventions, for autism spectrum, 1186
Mini-Cog test, 1149
Mini-Mental State Examination, 1149
Mirtazapine
- for depression, 996
- for insomnia, 1127
- for sleep disorders, 1128
- indications for, 933
- mechanism of action of, 935–936
- side effects of, 932, 996

Modafinil, 1136

Monoamine hypothesis, in depression, 987
Monoamine oxidase inhibitors, 936–937, 996
Montreal Cognitive Assessment, 1149
Mood disorders. See also Anxiety disorders; Depression.
- antipsychotics for, 949–950
- psychopharmacology for, 930–938

Mood Disorders Questionnaire, 1026
Mood stabilizers, 929–930, 938–943, 1032, 1034–1038
Mortality, in autism spectrum, 1176

Multiple somatic symptoms, 1079–1095
- comorbidities with, 1085–1087, 1089–1090
- treatment of, 1087–1091
- types of, 1081–1085

N

Naloxone, for opioid use disorders, 1115

Naltrexone
- for alcohol withdrawal, 1106–1109
- for opioid use disorders, 1115

Narcolepsy, 1125
- in anxiety, 1134
- in depression, 1132–1133
- in schizophrenia, 1135

National Institute for Health and Clinical Excellence guidelines, screening recommendations of, 974–976

National Institute of Mental Health Epidemiologic Catchment Area project, 1129

Nefazodone, 996, 1127

Neuroborreliosis, 1197

Neurohormones, abnormalities of, in borderline personality disorder, 1053

Neurosyphilis, 1196–1197

Nutrition, for autism spectrum, 1177

O

Obsessive-compulsive disorder
- cost of, 1010
- course of, 1012
- diagnosis of, 1009
- epidemiology of, 1012
- screening for, 1011
- treatment of, 1013, 1017–1018

Obstructive sleep apnea, 1125, 1128
- in anxiety, 1134
Obstructive (continued)
  in attention-deficit/hyperactivity disorder, 1136
  in depression, 1132
  in schizophrenia, 1135
QD4 gene, in bipolar disorder, 1026
Olanzapine, 944, 948, 950, 1034–1035, 1038
Older adults, psychiatric disorders in, 1145–1168
  anxiety, 971–972
  caregiver experiences in, 1154, 1162
  delirium, 1146–1148
  dementia, 950–951, 1148–1156
  depression, 971–972, 1156–1161
  substance abuse, 1161

P
Paliperidone, 948, 1034–1035
Panic disorder
  course of, 1011–1012
  diagnosis of, 1008–1009
  epidemiology of, 1011–1012
  screening for, 1011
  treatment of, 1013, 1017
Paraneoplastic syndromes, 1203
Paroxetine, 932–933, 996
Patient Health Questionnaire
  for bipolar disorder, 1038
  for depression, 961–964, 967, 971–972, 974, 985–986, 996
Pernicious anemia, neuropsychiatric manifestations of, 1201
Perpetuating, in Walker P-P-P model, 1084–1085
Perphenazine, 948
Persistent complex bereavement disorder, 1070
Persistent depressive disorder, 989
Personality, depression related to, 989
Pervasive Disorder Not Otherwise specified. See Autism spectrum.
Pharmacology. See Psychopharmacology; specific drugs and disorders.
Phenothiazines, 948
Physical examination, for autistic persons, 1182
Porphyrias, neuropsychiatric manifestations of, 1202
Posttraumatic stress disorder
  course of, 1012
  depression with, 988–989
  diagnosis of, 1009
  epidemiology of, 1012
  screening for, 968–970, 1011
  sleep disorders in, 1125, 1133
  treatment of, 1013, 1018
Prazosin, for anxiety disorders, 1018
Precipitating factors, in Walker P-P-P model, 1084–1085
Predisposing, in Walker P-P-P model, 1084–1085
Pregnancy
  bipolar disorder in, 1038–1039
substance abuse screening in, 1101
Primary Care – Posttraumatic Stress Disorder Screen, 969–970
PRIME-MD screening tool, 966–967, 1010
Progressive multifocal leukoencephalopathy, 1195
Progressive muscle relaxation, for depression, 992
Propranolol, for anxiety disorders, 1014, 1017
Psychiatric disorders
  addiction disorders. See Substance abuse disorders.
  adjustment disorder, 988, 1071–1074
  anxiety disorders. See Anxiety disorders.
  autism, 1169–1191
  bipolar disorders, 938–943, 1025–1048
  borderline personality disorders, 1033, 1049–1064
  grief reaction, 1069–1071
  in older adults, 950–951, 971–972, 1145–1168
  major depression, 981–1005
  medical conditions with, 1193–1208
  multiple somatic disorders in, 1079–1095
  psychopharmacology for, 927–958. See also specific drugs and disorders.
  screening for, 959–980
  seasonal affective disorders, 1066–1069, 1132
  sleep issues and. See Sleep disorders.
Psychodynamic therapy
  for borderline personality disorder, 1054–1055
  for depression, 992–993
Psychoeducation, for bipolar disorder, 1040
Psychopharmacology, 927–958. See also specific drugs and disorders.
  antipsychotics, 943–951
  for depression, 992, 994–998
  for mood disorders, 930–938
  general approach to, 927–930
  mood stabilizers, 938–943
Psychotherapy
  for adjustment disorder, 1074
  for anxiety disorders, 1013–1017
  for borderline personality disorder, 1054–1055
  for depression, 992–993
  for grief, 1071
  psychopharmacology with, 928

Q
Quetiapine, 944, 948, 950
  for bipolar disorder, 1034–1035, 1038
  for insomnia, 1127
  for sleep disorders, 1128
Quick Inventory of Depressive Symptomatology, 1038

R
Rapid Alcohol Problems Screen, 987–988
Relationships, unstable, in borderline personality disorder, 1051–1052
Relaxation therapy, for depression, 992
Restless leg syndrome, 1125
  in anxiety, 1134
  in attention-deficit/hyperactivity disorder, 1136
  in depression, 1132
  sleep disorders in, 1128
Risperidone, 944, 948–950
  for autism spectrum, 1185
  for bipolar disorder, 1034–1035
  for older adults, 950–951
Rivastigmine, for dementia, 1155

S
S4 model for somatization, 1086–1087
St. Johns wort
  for insomnia, 1127
  for seasonal affective disorder, 1068
Sarcoidosis, neuropsychiatric manifestations of, 1199
Schizoaffective disorder, versus bipolar disorder, 1033
Schizophrenia
  antipsychotics for, 948–949
  sleep disorders in, 1125, 1135
  versus bipolar disorder, 1033
Screening, for psychiatric disorders, 959–980
  anxiety disorders, 964–967, 974–976, 1010–1011, 1088
  asymptomatic, 960–961
  attention-deficit/hyperactivity disorder, 967–968
  depression, 961–964, 973–975, 1088
  limitations of tools for, 970–971
  major depression, 984–987
  new methods for, 972
  of older adults, 971–972
  posttraumatic stress disorder, 968–970
  recommendations for, 972–976
  substance abuse, 1098–1100
  targeted versus general, 972
Seasonal affective disorders, 1066–1069, 1132
Seasonal Health Questionnaire, 1066
Seasonal Pattern Assessment Questionnaire, 1066
Selective norepinephrine reuptake inhibitors, 934–935
  for anxiety disorders, 1013, 1017–1018
  for depression, 996–998
  for insomnia, 1126
  side effects of, 996–998
Selective serotonin reuptake inhibitors, 931–932, 934
  for anxiety disorders, 1013, 1017–1018
  for insomnia, 1126–1127
Self-care, for depression, 990–992
Sensory processing, in autism spectrum, 1180–1181, 1183–1184
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, 984, 998
Serotonin, in depression, 987
Serotonin syndrome, 934, 997
Sertraline, 932–933, 996
Single-item drug or alcohol screener, 1100
Sleep, deprivation of, depression in, 1130
Sleep disorders, 1123–1143. See also Obstructive sleep apnea.
  in anxiety disorders, 1125, 1133–1135
  in attention-deficit/hyperactivity disorder, 1125, 1135–1136
  in autism spectrum, 1178
  in bipolar disorder, 1130–1133
  in depression, 988, 991, 1125–1127, 1130–1133
  insomnia, 1124, 1128–1130
  neurobiology of, 1124
  treatment of, 1136
Sleep paralysis, 1125
  in anxiety, 1134–1135
  in depression, 1133
Sleepwalking, 1125
  in anxiety, 1134
  in depression, 1132
  sleep disorders in, 1128
Social anxiety disorder, 1008–1009
  cost of, 1010–1011
  course of, 1011
  epidemiology of, 1011
  treatment of, 1013, 1017
Societal rhythm therapy, for bipolar disorder, 1040
Somatic symptoms, multiple, 1079–1095
Spring/summer-onset seasonal affective disorder, 1066–1069
STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, 984, 998
STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disease) study, 1033–1034
Stimulants, for narcolepsy, 1133
Stress
  adjustment disorder in, 1071–1074
  somatic symptoms in, 1081–1082, 1088
Structured Clinical Interview for DSM disorders, 1071–1072
Substance abuse disorders, 1097–1122
  adjustment disorder with, 1073–1074
  alcohol, 1099–1108
  assessment of, 1098–1100
  depression with, 987–988, 991–992
  diagnosis of, 1098–1099
  in older adults, 1161
  opioids, 1108–1117
Subsyndromal depression, 989
Suicide risk
  in adjustment disorder, 1074
  in bipolar disorder, 1026–1027, 1041–1042
  in borderline personality disorder, 1051
  in depression, 1158–1159
Suicide (continued)
  in major depression, 990
  sleep disorders in, 1125, 1130
Symptom Driven Diagnostic System–Primary Care, 966–967
SYNE1 gene, in bipolar disorder, 1026
Syphilis, 1196–1197
Systematic Treatment Enhancement Program for Bipolar Disease (STEP-BD) study, 1033–1034
Systemic lupus erythematosus, neuropsychiatric manifestations of, 1198–1199

T
Teratogenic drugs, for bipolar disorder, 1039
Thioridazine, 948
Thyroid disorders, neuropsychiatric manifestations of, 1199–1200
Tobacco use. See Substance abuse.
Topiramate, for borderline personality disorder, 1055
Toxoplasmosis, neuropsychiatric manifestations of, 1195–1196
Transference-focused therapy, for borderline personality disorder, 1054–1055
Trazodone
  for depression, 996
  for insomnia, 1127
Tricyclic antidepressants, 936
Trifluoperazine, 948

U
United States Preventive Services Task Force, screening recommendations of, 974–976
Urine toxicology testing, for drugs of abuse, 1113

V
Valproate, 938–942
  for bipolar disorder, 1032, 1034, 1037, 1039
  for borderline personality disorder, 1055
Vascular dementia, 1152, 1155–1156
Venlafaxine, 932–933, 996
Ventriculoencephalitis, 1196
Violence, autism spectrum as victims of, 1178
Vitamin B₁ deficiency, neuropsychiatric manifestations of, 1201
Vitamin B₁₂ deficiency, neuropsychiatric manifestations of, 1201
Vitamin D, for seasonal affective disorder, 1068

W
Walker P-P-P model, for somatization, 1084–1085
Wender Utah Rating Scale, for ADHD screening, 968
Wernicke encephalopathy, 1201
Wilson disease, neuropsychiatric manifestations of, 1202
Winter-onset seasonal affective disorder, 1066–1069
Withdrawal, from alcohol abuse, 1103–1108
Y
Young Mania Rating Scale, 1032

Z
Ziprasidone, 944, 948, 1034, 1036
Zolpidem, for insomnia, 1126–1127, 1129